Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Breaking & Recent News Allogene Therapeutics Inc ALLO

Healthcare Biotechnology
Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It develops, manufactures, and commercializes UCART19, an allogeneic anti-CD19 chimeric antigen receptor (CAR) T cell product candidate for the treatment of patients with R/R CD19 positive B-cell... see more

Recent & Breaking News (NDAQ:ALLO)

Allogene Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update

GlobeNewswire 6 days ago

Allogene Therapeutics Announces Participation in Upcoming Investor Conferences

GlobeNewswire February 5, 2026

Allogene Therapeutics Positions 2026 as a Program-Defining Year for Scalable, Real-World Allogeneic CAR T

GlobeNewswire January 8, 2026

Allogene Therapeutics Reports Favorable Result for Servier in Arbitration with Cellectis

GlobeNewswire December 15, 2025

Allogene Therapeutics Announces Participation in Upcoming Investor Conferences

GlobeNewswire November 10, 2025

Allogene Therapeutics Reports Third Quarter 2025 Financial Results and Business Update

GlobeNewswire November 6, 2025

Allogene Therapeutics Announces ALPHA3 Trial-in-Progress Poster Presentation at ASH Annual Meeting

GlobeNewswire November 3, 2025

Allogene Therapeutics to Report Third Quarter 2025 Financial Results and Provide Business Update

GlobeNewswire October 30, 2025

Allogene Therapeutics Announces Participation in Upcoming Investor Conference

GlobeNewswire August 27, 2025

Allogene Therapeutics Reports Second Quarter 2025 Financial Results and Business Update

GlobeNewswire August 13, 2025

Allogene Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update

GlobeNewswire August 6, 2025

Allogene Therapeutics Moves Forward with Standard Fludarabine and Cyclophosphamide (FC) Lymphodepletion Regimen in the ALPHA3 Trial for Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation for Large B-Cell Lymphoma

GlobeNewswire August 1, 2025

Allogene Therapeutics Provides Updated Phase 1 Data Highlighting Durable Responses with ALLO-316 in Heavily Pretreated Advanced Renal Cell Carcinoma at ASCO

GlobeNewswire June 1, 2025

Allogene Therapeutics Announces Participation in Upcoming Investor Conferences

GlobeNewswire May 23, 2025

Allogene Therapeutics Announces ASCO 2025 Abstract Publication Featuring Oral Presentation of ALLO-316 in Kidney Cancer and ALPHA3 TIP Poster for Cema-Cel

GlobeNewswire May 22, 2025

Allogene Therapeutics Reports First Quarter 2025 Financial Results and Business Update

GlobeNewswire May 13, 2025

Allogene Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update

GlobeNewswire May 6, 2025

Allogene Therapeutics to Present Updated ALLO-316 Clinical Results in Kidney Cancer in Oral Presentation and ALPHA3 Trial-in-Progress Poster for Cema-Cel at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

GlobeNewswire April 23, 2025

Allogene Granted Three U.S. FDA Fast Track Designations (FTD) for ALLO-329, a Next-Generation Dual-Targeted CD19/CD70 Allogeneic CAR T, for the Treatment of Lupus, Myositis and Scleroderma

GlobeNewswire April 7, 2025

Allogene Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Update

GlobeNewswire March 13, 2025

Podcasts